The role of neuroinflammation-related regulatory targets in the treatment for Parkinson's disease

Parkinson's disease (PD) is a neurodegenerative disease characterized by the degeneration of dopaminergic neurons. The present therapeutic drugs for PD can only alleviate the patients' symptoms, but cannot prevent or delay progression of the disease. Great efforts have been made in the identification of new molecular targets that can prevent or delay the loss of dopaminergic neurons. Growing evidences support the key role of neuroinflammation in the pathogenesis of PD, featured by the activation of glial cells and many enzymes and receptors. This review will provide an overview of the enzymes and receptors closely related to neuroinflammation, which have a potential in the prevention or treatment of the disease.